CEO: Mary Kerr

Advent Contact: Kaasim Mahmood/Raj Parekh

Novel neurokinin antagonists

NeRRe Therapeutics is a UK based clinical-stage company developing a unique pipeline of three neurokinin (NK)-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity. The lead compound orvepitant, a potent and highly selective NK-1 receptor antagonist, is in a Phase 2b multinational trial to assess its benefit in patients with chronic refractory cough. It has the potential to be a first-in-class once-daily oral therapy, bringing significant benefits to sufferers of this incapacitating condition for which there are currently no approved medicines.

Advent founded NeRRe in 2012. NeRRe completed a £23M private financing in 2016.


NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round